BioClin Therapeutics, Inc., Completes $50 Million Series B Financing with Addition of New Investors
BioClin Therapeutics, Inc., a clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody for metastatic bladder cancer, announced today expansion of its Series B financing to $50 million to broaden its clinical development activities. New investors, Sectoral Asset Management and INKEF Capital, joined existing investors Sofinnova Ventures, Ysios Capital, HealthCap, Tekla Capital Management funds, and Life Sciences Partners (LSP) in the round. Since its founding, the company has raised a total of $79 million.
The proceeds from this financing will be used to advance the company’s lead development candidate, B-701, for the treatment of patients with metastatic bladder cancer, or metastatic urothelial carcinoma (mUC). “This financing supports our Phase 2 trials evaluating B-701 both as a single agent, as well as in combination with pembrolizumab and separately with docetaxel. We anticipate completing enrollment in these Phase 2 studies by the second half of 2018, with initial data expected by year-end,” said Stephen Lau, CEO of BioClin Therapeutics.
“We are delighted that Sectoral Asset Management and INKEF Capital have joined the BioClin investor syndicate. The additional funding will allow the Company to move forward with the only targeted biologic specific for FGFR3 in clinical development for bladder cancer,” said David Kabakoff of Sofinnova and board member of BioClin Therapeutics.
About BioClin Therapeutics, Inc.
BioClin Therapeutics, Inc. is a privately-held clinical stage biotechnology company developing biologics to address medical conditions in areas of high unmet need. The company is focused on FGFR3 (fibroblast growth factor receptor 3), a driver mutation in metastatic bladder cancer and potentially other cancers. The company’s lead program, B-701, is the only targeted biologic specific for FGFR3 in clinical development. BioClin has ongoing clinical studies in metastatic bladder cancer including B-701 monotherapy, and B-701 in combination with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor.
For more information, please visit BioClin’s website: www.bioclintherapeutics.com
This press release contains forward-looking statements about the business and prospects of BioClin Therapeutics, Inc., which involve risks and uncertainties, including, without limitation, statements about the timing and plans to conduct clinical trials of B-701 in mUC. These risks and uncertainties include, among others: timing of enrollment in and results of the clinical trials; safety of B-701 alone or in combination with other therapies; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning B-701. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. BioClin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioClin Therapeutics, Inc.
Chief Executive Officer
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Lion/Gem Luxembourg 3 S.a.r.l. Announce Second Quarter Results for FY 201824.5.2018 11:00 | Tiedote
The Second Quarter results for FY18 for Lion/Gem Luxembourg 3 S.a.r.l. (associated with Young’s Seafood Limited) will be made available on our Investor Relations website on May 24, 2018. The Second Quarter results call for investors that accompanies this information is scheduled to take place at 13:00 BST on May 24, 2018. The Second Quarter covers the quarter to 31 March 2018; the financial year end for Lion/Gem Luxembourg 3 S.a.r.l. is September 30, 2018. For further information: If you are an investor or a potential investor in the 8¼%/ 9% Senior PIK Notes due 2019, of Lion/Gem Luxembourg 3 S.a.r.l., and would like access to this information, please register your interest on our Investor Relations website: https://youngsseafood.co.uk/investors/. If you have any questions about the registration process or need further information, please do not hesitate to contact Nicholas Donnelly, Communications Manager at Young’s Seafood: firstname.lastname@example.org This announcement cont
Rakuten Announces Signing of Andrés Iniesta to Vissel Kobe24.5.2018 10:55 | Tiedote
Rakuten Vissel Kobe, Inc., a Rakuten Group company, today announced that Andrés Iniesta will join Vissel Kobe, the much-loved Western Japan football club, after an historic career at FC Barcelona, one of the most iconic and beloved football clubs in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180524005463/en/ Since the beginning of his professional career with FC Barcelona in 2002, Iniesta has not only become one of the top players in the world, he is also renowned for his embodiment of the philosophy and values of the iconic club, with his commitment to teamwork and beautiful play. With a social media presence that includes over 74 million followers, Iniesta is also known as a global influencer. Iniesta developed his football career through the FC Barcelona cantera, the club’s unique youth league system that fosters young players, and his addition to Vissel Kobe is not only expected to draw in fans to see his
Poseidon Foundation Launches First Retail Platform That Allows Consumers to Support Climate Action Using Blockchain Technology24.5.2018 10:13 | Tiedote
The world’s first retail platform that connects consumers to their own carbon footprint has been launched in London by non-profit ogranisation the Poseidon Foundation (“Poseidon”). Poseidon’s platform uses blockchain technology to integrate carbon markets into transactions at the point-of-sale, giving retailers and their customers the opportunity to support forestry conservation projects around the world when they buy and sell everyday items, and in turn support action on climate change. The retail platform launched on 1st May, and a pilot is currently underway at Ben & Jerry’s newest ice cream Scoop Shop in Wardour Street, London. For every scoop of ice cream sold the values-led ice cream company is contributing towards carbon credits from a forest conservation project in Peru, and is offering their customers the opportunity to join them in taking action at the point of sale, using blockchain technology. Ben & Jerry’s has been vocal for many years on the issue of climate justice, incl
GSMA Announces New Events and Programmes Taking Place at Mobile World Congress Shanghai 201824.5.2018 10:00 | Tiedote
The GSMA today provided further details on the array of events and programmes that will be available to attendees at the 2018 GSMA Mobile World Congress Shanghai, including partner and co-located events; GSMA Forums, Seminars and Workshops; and Partner Programmes. Mobile World Congress Shanghai will be held 27-29 June at the Shanghai New International Expo Centre (SNIEC). “We’ve expanded the number of programmes and events at Mobile World Congress Shanghai, featuring everything from sports and fitness to service robots to the intersection of art and innovation, and beyond,” said Michael O’Hara, Chief Marketing Officer, GSMA. “We have a very exciting event lined up and we are looking forward to bringing the mobile world together in Shanghai next month.” New Details on Partner and Co-located Events at Mobile World Congress Shanghai The GSMA today provided an update on the partner and co-located events that will be held concurrently with Mobile World Congress Shanghai, offering attendees
FUELSAVE GmbH: FS MARINE+ is Revolutionizing Shipping Efficiency, Helping Ship Operators to Become Cleaner & More Profitable for a Unique Win-Win24.5.2018 10:00 | Tiedote
FUELSAVE GmbH is launching a revolutionary efficiency enhancement technology for Diesel (MGO / MDO) and Heavy-Fuel-Oil (HFO) engines on maritime vessels, which has been field & laboratory proven to significantly reduce fuel consumption and save contractually guaranteed 10% of the overall fuel costs, to lower the OPEX and increase profitability, while significantly reducing emissions ( CO2 by 10-15%, FSN by 40%, NOx by 30-70% etc.) for saving the environment and reducing Green House Gases (GHG) with a visible exhaust smoke reduction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180524005120/en/ FS MARINE+ Next Generation Efficiency Enhancement for Maritime Vessels The company's breakthrough unit, called FS MARINE+ is an engine efficiency enhancement solution, with an onboard hydrogen syngas generator, which combines different processes of gas and liquid water methanol injection to significantly improve combustion efficiency
Elliott Advisors (UK) Limited Statement on thyssenkrupp AG24.5.2018 09:30 | Tiedote
Further to recent media speculation, funds advised by Elliott Advisors (UK) Limited (“Elliott”) confirm that they are significant shareholders in thyssenkrupp AG (“thyssenkrupp” or the “Company”). The funds’ position in ordinary shares is such that it does not exceed, as of today, the thresholds mandating disclosure under applicable German laws. Elliott will make any disclosure regarding its holdings in the shares of thyssenkrupp no later than when and as required by German law. Elliott’s approach to its investment in thyssenkrupp is consistent with its approach to all its investments. Elliott has spent significant time and resources analysing the Company, performing exhaustive research on its prospects, competitive positioning and valuation. Elliott believes thyssenkrupp has significant scope for operational improvement which would benefit all stakeholders and looks forward to engaging in a constructive dialogue with them in the near future, including with the supervisory and manageme
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme